person · Reporting owner

Patel Sandip I

Disclosed activity across 5 companies

Tapewire entity: 30204
SEC CIK: 0001843601

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Akari Therapeutics PlcAKTX · Entity 7692	Director	December 16, 2025	December 19, 2025
AtlasClear Holdings, Inc.ATCH · Entity 7491	Director · CFO and General Counsel	October 01, 2026	October 03, 2026
Monterey Innovation Acquisition CorpMTRY · Entity 114547	Director · 10% owner	March 09, 2023	March 14, 2023
Peak Bio, Inc.PKBO · Entity 85431	Director	November 14, 2024	November 18, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akari Therapeutics Plc

Report date December 16, 2025 · Filed December 19, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Warrants to purchase American Depositary Shares ("ADRs")SEC Table II · derivative / convertible security · Conversion / exercise price $0.39	Direct	247,462	Reported balance After 2025-12-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-12-16 · Purchase · Acquired 247,462 · Balance 247,462 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 247,462 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 247,462 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.
Pre-Funded Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	247,462	Reported balance After 2025-12-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-16 · Purchase · Acquired 247,462 · Balance 247,462 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 247,462 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 247,462 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F7: Conversion Exercise Price of Security is $0.00001 F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.
Pre-Funded Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	154,664	Reported balance After 2025-12-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-16 · Purchase · Acquired 154,664 · Balance 154,664 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the "Note Exchange Unregistered Warrants"). F7: Conversion Exercise Price of Security is $0.00001 F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.
Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.39	Direct	154,664	Reported balance After 2025-12-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-16 · Purchase · Acquired 154,664 · Balance 154,664 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the "Note Exchange Unregistered Warrants"). F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.

Filing footnotes · ownership attribution and instrument terms

F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.

F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 247,462 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 247,462 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.

F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.

F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the "Note Exchange Unregistered Warrants").

F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.

F7: Conversion Exercise Price of Security is $0.00001

AtlasClear Holdings, Inc.

Report date October 01, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.20 · Expires 2033-10-01	Direct	777,332	Reported balance After 2026-10-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-10-01 · Grant · Acquired 777,332 · Balance 777,332 F1: The option vests in three equal annual installments beginning October 1, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in three equal annual installments beginning October 1, 2027.

Monterey Innovation Acquisition Corp

Report date March 09, 2023 · Filed March 14, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,417,500	Last balance in matching sequence After 2023-03-09 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2023-03-09 · Sale · Disposed 570,000 · Balance 1,342,500 F1: The shares of common stock (the "founder shares") of Monterey Innovation Acquisition Corp. (the "Company") are held directly by NorthStar Bio Ventures, LLC (the "NorthStar Co-Sponsor"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. F2: In connection with the Company's previously disclosed management transition, and pursuant to share transfer agreements dated March 9, 2023, NorthStar Co-Sponsor transferred (i) 478,125 founder shares to Chardan Monterey Investments LLC and (ii) 30,625 founder shares to each of the Company's three new directors, in each case, at a price of $0.006 per share. Row 2 · 2023-03-09 · Other · Acquired 75,000 · Balance 1,417,500 F1: The shares of common stock (the "founder shares") of Monterey Innovation Acquisition Corp. (the "Company") are held directly by NorthStar Bio Ventures, LLC (the "NorthStar Co-Sponsor"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. F3: On March 9, 2023, Sanjeev Satyal resigned as the Company's Chief Executive Officer and, pursuant to an assignment dated March 9, 2023, transferred back to NorthStar Co-Sponsor 75,000 of the founder shares that he received from NorthStar Co-Sponsor prior to the Company's initial public offering.
Common StockSEC Table I · non-derivative	Direct	35,000	Reported balance Holding disclosure · report date 2023-03-09 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 35,000

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock (the "founder shares") of Monterey Innovation Acquisition Corp. (the "Company") are held directly by NorthStar Bio Ventures, LLC (the "NorthStar Co-Sponsor"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F2: In connection with the Company's previously disclosed management transition, and pursuant to share transfer agreements dated March 9, 2023, NorthStar Co-Sponsor transferred (i) 478,125 founder shares to Chardan Monterey Investments LLC and (ii) 30,625 founder shares to each of the Company's three new directors, in each case, at a price of $0.006 per share.

F3: On March 9, 2023, Sanjeev Satyal resigned as the Company's Chief Executive Officer and, pursuant to an assignment dated March 9, 2023, transferred back to NorthStar Co-Sponsor 75,000 of the founder shares that he received from NorthStar Co-Sponsor prior to the Company's initial public offering.

Peak Bio, Inc.

Report date November 14, 2024 · Filed November 18, 2024

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2024-11-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-11-14 · Conversion · Acquired 763,316 · Balance 763,316 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F2: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). Row 2 · 2024-11-14 · Disposition to issuer · Disposed 763,316 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2024-11-14 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-11-14 · Disposition to issuer · Disposed 67,735 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F4: The securities are held by QuestBio LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2024-11-14 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2024-11-14 · Disposition to issuer · Disposed 68,891 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F5: The securities are held by Davis Island Ventures, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2024-11-14 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2024-11-14 · Disposition to issuer · Disposed 47,364 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F6: The securities are held by Innovative Lifesci Investments, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.
Convertible NotesSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-11-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-11-14 · Conversion · Disposed Not disclosed · Balance 0 F2: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80	Direct	Reported balance After 2024-11-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-11-14 · Disposition to issuer · Disposed 400,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F7: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").

F2: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock").

F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent.

F4: The securities are held by QuestBio LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.

F5: The securities are held by Davis Island Ventures, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.

F6: The securities are held by Innovative Lifesci Investments, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.

F7: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Quantum FinTech Acquisition Corp

Report date February 09, 2024 · Filed February 17, 2024

Section 16 reporting ended · disclosed 2024-02-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-02-09 transaction · row 1 1 source row Row 1 · 2024-02-09 · Disposition to issuer · Disposed 41,334 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated November 16, 2022, as amended, by and among (i) the Issuer, (ii) Calculator New Pubco, Inc., a Delaware corporation and a wholly-owned Subsidiary of Issuer ("New Pubco"), (iii) Calculator Merger Sub 1, Inc., a Delaware corporation and a wholly-owned Subsidiary of New Pubco ("Merger Sub 1"), (iv) Calculator Merger Sub 2, Inc., a Delaware corporation and a wholly-owned Subsidiary of New Pubco, (v) AtlasClear, Inc., a Wyoming corporation, (vi) Atlas FinTech Holdings Corp, a Delaware corporation and (vii) Robert McBey, on February 9, 2024, the Issuer merged with and into Merger Sub 1, with Issuer surviving as a wholly-owned subsidiary of New Pubco (the "Business Combination"). As a result of the Business Combination, each issued and outstanding share of common stock of the Issuer was exchanged for one share of common stock of New PubCo.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Business Combination Agreement, dated November 16, 2022, as amended, by and among (i) the Issuer, (ii) Calculator New Pubco, Inc., a Delaware corporation and a wholly-owned Subsidiary of Issuer ("New Pubco"), (iii) Calculator Merger Sub 1, Inc., a Delaware corporation and a wholly-owned Subsidiary of New Pubco ("Merger Sub 1"), (iv) Calculator Merger Sub 2, Inc., a Delaware corporation and a wholly-owned Subsidiary of New Pubco, (v) AtlasClear, Inc., a Wyoming corporation, (vi) Atlas FinTech Holdings Corp, a Delaware corporation and (vii) Robert McBey, on February 9, 2024, the Issuer merged with and into Merger Sub 1, with Issuer surviving as a wholly-owned subsidiary of New Pubco (the "Business Combination"). As a result of the Business Combination, each issued and outstanding share of common stock of the Issuer was exchanged for one share of common stock of New PubCo.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 01, 2026 Filed Oct 3, 2026 00:34 UTC	AtlasClear Holdings, Inc. ATCH · Entity 7491	GrantStock Option (right to buy) · Derivative	777,332	$0.00 Strike: $0.20	$0.00	Disclosure SEC source: 0001493152-26-045546 · ownership.xml · derivative · entry 1 Patel Sandip I · CIK 0001843601 · Director · CFO and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 777,332 Underlying: Common Stock · 777,332 shares Expires 2033-10-01 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning October 1, 2027. Read SEC document
September 25, 2026 Filed Sep 28, 2026 21:01 UTC Amendment	AtlasClear Holdings, Inc. ATCH · Entity 7491	PurchaseCommon Stock	50,000	$0.20	$9,875.00	Disclosure SEC source: 0001493152-26-044629 · ownership.xml · nonDerivative · entry 2 Patel Sandip I · CIK 0001843601 · Director · CFO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 905,130 F1 · kind: On September 28, 2026, the Reporting Person filed a Form 4 which inadvertently used Transaction Code "A" to report certain open market purchases of shares of Common Stock. As reported in this amendment, the correct Transaction Code is "P." Read SEC document
September 25, 2026 Filed Sep 28, 2026 13:26 UTC	AtlasClear Holdings, Inc. ATCH · Entity 7491	GrantCommon Stock	50,000	$0.20	$9,875.00	Disclosure SEC source: 0001493152-26-044471 · ownership.xml · nonDerivative · entry 2 Patel Sandip I · CIK 0001843601 · Director · CFO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 905,130 Read SEC document
September 24, 2026 Filed Sep 28, 2026 21:01 UTC Amendment	AtlasClear Holdings, Inc. ATCH · Entity 7491	PurchaseCommon Stock	50,000	$0.22	$10,865.00	Disclosure SEC source: 0001493152-26-044629 · ownership.xml · nonDerivative · entry 1 Patel Sandip I · CIK 0001843601 · Director · CFO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 855,130 F1 · kind: On September 28, 2026, the Reporting Person filed a Form 4 which inadvertently used Transaction Code "A" to report certain open market purchases of shares of Common Stock. As reported in this amendment, the correct Transaction Code is "P." Read SEC document
September 24, 2026 Filed Sep 28, 2026 13:26 UTC	AtlasClear Holdings, Inc. ATCH · Entity 7491	GrantCommon Stock	50,000	$0.22	$10,865.00	Disclosure SEC source: 0001493152-26-044471 · ownership.xml · nonDerivative · entry 1 Patel Sandip I · CIK 0001843601 · Director · CFO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 855,130 Read SEC document
July 14, 2026 Filed Jul 17, 2026 00:21 UTC	AtlasClear Holdings, Inc. ATCH · Entity 7491	GrantStock Option (right to buy) · Derivative	731,030	$0.00 Strike: $0.18	$0.00	Disclosure SEC source: 0001493152-26-033630 · ownership.xml · derivative · entry 2 Patel Sandip I · CIK 0001843601 · Director · CFO and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,030 Underlying: Common Stock · 731,030 shares Expires 2031-06-30 Read SEC document
July 14, 2026 Filed Jul 17, 2026 00:21 UTC	AtlasClear Holdings, Inc. ATCH · Entity 7491	GrantStock Option (right to buy) · Derivative	45,000	$0.00 Strike: $0.18	$0.00	Disclosure SEC source: 0001493152-26-033630 · ownership.xml · derivative · entry 1 Patel Sandip I · CIK 0001843601 · Director · CFO and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-01-26 Read SEC document
December 16, 2025 Filed Dec 19, 2025 02:57 UTC	Akari Therapeutics Plc AKTX · Entity 7692	PurchasePre-Funded Warrants to purchase ADRs · Derivative	154,664	$0.40 Strike: $0.00	$62,499.72	Disclosure SEC source: 0001493152-25-028421 · ownership.xml · derivative · entry 4 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,664 Underlying: American Depositary Shares representing Ordinary Shares · 154,664 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the "Note Exchange Unregistered Warrants"). F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document
December 16, 2025 Filed Dec 19, 2025 02:57 UTC	Akari Therapeutics Plc AKTX · Entity 7692	PurchaseWarrants to purchase ADRs · Derivative	154,664	Not disclosed Strike: $0.39	Not disclosed	Disclosure SEC source: 0001493152-25-028421 · ownership.xml · derivative · entry 3 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,664 Underlying: American Depositary Shares representing Ordinary Shares · 154,664 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the "Note Exchange Unregistered Warrants"). F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document
December 16, 2025 Filed Dec 19, 2025 02:57 UTC	Akari Therapeutics Plc AKTX · Entity 7692	PurchasePre-Funded Warrants to purchase ADRs · Derivative	247,462	$0.40 Strike: $0.00	$99,999.39	Disclosure SEC source: 0001493152-25-028421 · ownership.xml · derivative · entry 2 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,462 Underlying: American Depositary Shares representing Ordinary Shares · 247,462 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 247,462 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 247,462 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document
December 16, 2025 Filed Dec 19, 2025 02:57 UTC	Akari Therapeutics Plc AKTX · Entity 7692	PurchaseWarrants to purchase American Depositary Shares ("ADRs") · Derivative	247,462	Not disclosed Strike: $0.39	Not disclosed	Disclosure SEC source: 0001493152-25-028421 · ownership.xml · derivative · entry 1 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,462 Underlying: American Depositary Shares representing Ordinary Shares · 247,462 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 247,462 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 247,462 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:00 UTC	Akari Therapeutics Plc AKTX · Entity 7692	GrantStock Option (Right to Buy) · Derivative	225,000	$0.00 Strike: $1.50	$0.00	Disclosure SEC source: 0000950170-25-043935 · ownership.xml · derivative · entry 7 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: American Depositary Shares representing Ordinary Shares · 225,000 shares Expires 2035-03-20 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:00 UTC	Akari Therapeutics Plc AKTX · Entity 7692	GrantStock Option (Right to Buy) · Derivative	175,000	$0.00 Strike: $1.50	$0.00	Disclosure SEC source: 0000950170-25-043935 · ownership.xml · derivative · entry 6 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: American Depositary Shares representing Ordinary Shares · 175,000 shares Expires 2035-03-20 F2 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document
March 06, 2025 Filed Apr 29, 2025 21:00 UTC	Akari Therapeutics Plc AKTX · Entity 7692	GrantSeries B Warrants (Right to Buy) · Derivative	44,642	$1.12 Strike: $0.87	$49,999.04	Disclosure SEC source: 0000950170-25-060298 · ownership.xml · derivative · entry 7 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,642 Underlying: American Depositary Shares representing Ordinary Shares · 44,642 shares Expires 2030-03-06 F2 · kind: On April 25, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On April 25, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document
March 06, 2025 Filed Apr 29, 2025 21:00 UTC	Akari Therapeutics Plc AKTX · Entity 7692	GrantSeries A Warrants (Right to Buy) · Derivative	44,642	$1.12 Strike: $0.87	$49,999.04	Disclosure SEC source: 0000950170-25-060298 · ownership.xml · derivative · entry 6 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,642 Underlying: American Depositary Shares representing Ordinary Shares · 44,642 shares Expires 2026-03-06 F2 · kind: On April 25, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On April 25, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document
March 06, 2025 Filed Apr 29, 2025 21:00 UTC	Akari Therapeutics Plc AKTX · Entity 7692	GrantAmerican Depositary Shares representing Ordinary Shares	44,642	$1.12	$49,999.04	Disclosure SEC source: 0000950170-25-060298 · ownership.xml · nonDerivative · entry 1 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 496,499 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On April 25, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On April 25, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. Read SEC document
November 14, 2024 Filed Nov 18, 2024 23:55 UTC	Peak Bio, Inc. PKBO · Entity 85431	Disposition to issuerStock Option (Right to Buy) · Derivative	400,000	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0000950170-24-128153 · ownership.xml · derivative · entry 7 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F7 · kind: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio. F7 · derivative.exercise_date: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio. F7 · derivative.expiration_date: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio. Read SEC document
November 14, 2024 Filed Nov 18, 2024 23:55 UTC	Peak Bio, Inc. PKBO · Entity 85431	ConversionConvertible Notes · Derivative	Not disclosed	Not disclosed	$275,500.00	Disclosure SEC source: 0000950170-24-128153 · ownership.xml · derivative · entry 6 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 763,316 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F2 · kind: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F2 · price: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F2 · derivative.exercise_date: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F2 · derivative.expiration_date: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). Read SEC document
November 14, 2024 Filed Nov 18, 2024 23:55 UTC	Peak Bio, Inc. PKBO · Entity 85431	Disposition to issuerCommon Stock	47,364	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-128153 · ownership.xml · nonDerivative · entry 5 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3 · kind: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F3 · price: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F6 · ownership.nature: The securities are held by Innovative Lifesci Investments, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares. Read SEC document
November 14, 2024 Filed Nov 18, 2024 23:55 UTC	Peak Bio, Inc. PKBO · Entity 85431	Disposition to issuerCommon Stock	68,891	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-128153 · ownership.xml · nonDerivative · entry 4 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3 · kind: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F3 · price: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F5 · ownership.nature: The securities are held by Davis Island Ventures, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares. Read SEC document
November 14, 2024 Filed Nov 18, 2024 23:55 UTC	Peak Bio, Inc. PKBO · Entity 85431	Disposition to issuerCommon Stock	67,735	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-128153 · ownership.xml · nonDerivative · entry 3 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3 · kind: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F3 · price: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F4 · ownership.nature: The securities are held by QuestBio LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares. Read SEC document
November 14, 2024 Filed Nov 18, 2024 23:55 UTC	Peak Bio, Inc. PKBO · Entity 85431	Disposition to issuerCommon Stock	763,316	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-128153 · ownership.xml · nonDerivative · entry 2 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3 · kind: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F3 · price: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. Read SEC document
November 14, 2024 Filed Nov 18, 2024 23:55 UTC	Peak Bio, Inc. PKBO · Entity 85431	ConversionCommon Stock	763,316	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-128153 · ownership.xml · nonDerivative · entry 1 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 763,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F2 · kind: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F2 · price: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). Read SEC document
March 20, 2024 Filed Apr 16, 2024 21:26 UTC	AtlasClear Holdings, Inc. ATCH · Entity 7491	OtherWarrants · Derivative	354,088	$0.00 Strike: $11.50	$0.00	Disclosure SEC source: 0001104659-24-047909 · tm2411883-15_4seq1.xml · derivative · entry 2 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,088 Underlying: Common Stock · 354,088 shares Expires not disclosed F2 · kind: Represents private placement warrants of the Issuer transferred from Quantum Ventures to the Reporting Person for no consideration. These warrants became exercisable upon consummation of the Business Combination and will expire five years after the Closing, as described in the Issuer's registration statement on Form S-4 (File No. 333-271665), as amended. F2 · price: Represents private placement warrants of the Issuer transferred from Quantum Ventures to the Reporting Person for no consideration. These warrants became exercisable upon consummation of the Business Combination and will expire five years after the Closing, as described in the Issuer's registration statement on Form S-4 (File No. 333-271665), as amended. F2 · derivative.exercise_date: Represents private placement warrants of the Issuer transferred from Quantum Ventures to the Reporting Person for no consideration. These warrants became exercisable upon consummation of the Business Combination and will expire five years after the Closing, as described in the Issuer's registration statement on Form S-4 (File No. 333-271665), as amended. F2 · derivative.expiration_date: Represents private placement warrants of the Issuer transferred from Quantum Ventures to the Reporting Person for no consideration. These warrants became exercisable upon consummation of the Business Combination and will expire five years after the Closing, as described in the Issuer's registration statement on Form S-4 (File No. 333-271665), as amended. Read SEC document
February 09, 2024 Filed Feb 17, 2024 00:13 UTC	Quantum FinTech Acquisition Corp QFTA · Entity 94086	Disposition to issuerCommon Stock	41,334	Not disclosed	Not disclosed	Disclosure SEC source: 0001474506-24-000043 · primary_doc.xml · nonDerivative · entry 1 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Business Combination Agreement, dated November 16, 2022, as amended, by and among (i) the Issuer, (ii) Calculator New Pubco, Inc., a Delaware corporation and a wholly-owned Subsidiary of Issuer ("New Pubco"), (iii) Calculator Merger Sub 1, Inc., a Delaware corporation and a wholly-owned Subsidiary of New Pubco ("Merger Sub 1"), (iv) Calculator Merger Sub 2, Inc., a Delaware corporation and a wholly-owned Subsidiary of New Pubco, (v) AtlasClear, Inc., a Wyoming corporation, (vi) Atlas FinTech Holdings Corp, a Delaware corporation and (vii) Robert McBey, on February 9, 2024, the Issuer merged with and into Merger Sub 1, with Issuer surviving as a wholly-owned subsidiary of New Pubco (the "Business Combination"). As a result of the Business Combination, each issued and outstanding share of common stock of the Issuer was exchanged for one share of common stock of New PubCo. Read SEC document
February 09, 2024 Filed Apr 16, 2024 21:26 UTC	AtlasClear Holdings, Inc. ATCH · Entity 7491	OtherCommon Stock	201,860	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-047909 · tm2411883-15_4seq1.xml · nonDerivative · entry 1 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,194 F1 · shares: On February 9, 2024, the Issuer (f/k/a Calculator New Pubco, Inc.) consummated its initial business combination (the "Business Combination") pursuant to the business combination agreement dated November 16, 2022, as amended, among Quantum FinTech Acquisition Corporation ("Quantum"), AtlasClear, Inc., a Wyoming corporation, and the other parties thereto. Represents shares of the Issuer's common stock transferred by Quantum Ventures LLC ("Quantum Ventures"), to the Reporting Person for no consideration in connection with the closing of the Business Combination (the "Closing"). F1 · price: On February 9, 2024, the Issuer (f/k/a Calculator New Pubco, Inc.) consummated its initial business combination (the "Business Combination") pursuant to the business combination agreement dated November 16, 2022, as amended, among Quantum FinTech Acquisition Corporation ("Quantum"), AtlasClear, Inc., a Wyoming corporation, and the other parties thereto. Represents shares of the Issuer's common stock transferred by Quantum Ventures LLC ("Quantum Ventures"), to the Reporting Person for no consideration in connection with the closing of the Business Combination (the "Closing"). Read SEC document
March 09, 2023 Filed Mar 14, 2023 00:44 UTC	Monterey Innovation Acquisition Corp MTRY · Entity 114547	OtherCommon Stock	75,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-031926 · tm239467-7_4seq1.xml · nonDerivative · entry 2 Patel Sandip I · CIK 0001843601 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,417,500 F1 · security: The shares of common stock (the "founder shares") of Monterey Innovation Acquisition Corp. (the "Company") are held directly by NorthStar Bio Ventures, LLC (the "NorthStar Co-Sponsor"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. F3 · shares: On March 9, 2023, Sanjeev Satyal resigned as the Company's Chief Executive Officer and, pursuant to an assignment dated March 9, 2023, transferred back to NorthStar Co-Sponsor 75,000 of the founder shares that he received from NorthStar Co-Sponsor prior to the Company's initial public offering. F3 · price: On March 9, 2023, Sanjeev Satyal resigned as the Company's Chief Executive Officer and, pursuant to an assignment dated March 9, 2023, transferred back to NorthStar Co-Sponsor 75,000 of the founder shares that he received from NorthStar Co-Sponsor prior to the Company's initial public offering. F1 · ownership.nature: The shares of common stock (the "founder shares") of Monterey Innovation Acquisition Corp. (the "Company") are held directly by NorthStar Bio Ventures, LLC (the "NorthStar Co-Sponsor"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
March 09, 2023 Filed Mar 14, 2023 00:44 UTC	Monterey Innovation Acquisition Corp MTRY · Entity 114547	SaleCommon Stock	570,000	$0.01	$3,420.00	Disclosure SEC source: 0001104659-23-031926 · tm239467-7_4seq1.xml · nonDerivative · entry 1 Patel Sandip I · CIK 0001843601 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,342,500 F1 · security: The shares of common stock (the "founder shares") of Monterey Innovation Acquisition Corp. (the "Company") are held directly by NorthStar Bio Ventures, LLC (the "NorthStar Co-Sponsor"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. F2 · shares: In connection with the Company's previously disclosed management transition, and pursuant to share transfer agreements dated March 9, 2023, NorthStar Co-Sponsor transferred (i) 478,125 founder shares to Chardan Monterey Investments LLC and (ii) 30,625 founder shares to each of the Company's three new directors, in each case, at a price of $0.006 per share. F2 · price: In connection with the Company's previously disclosed management transition, and pursuant to share transfer agreements dated March 9, 2023, NorthStar Co-Sponsor transferred (i) 478,125 founder shares to Chardan Monterey Investments LLC and (ii) 30,625 founder shares to each of the Company's three new directors, in each case, at a price of $0.006 per share. F1 · ownership.nature: The shares of common stock (the "founder shares") of Monterey Innovation Acquisition Corp. (the "Company") are held directly by NorthStar Bio Ventures, LLC (the "NorthStar Co-Sponsor"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
February 05, 2021 Filed Feb 10, 2021 01:55 UTC	Quantum FinTech Acquisition Corp QFTA.U · Entity 94086	PurchaseCommon Stock	501	$10.34	$5,177.84	Disclosure SEC source: 0001213900-21-007855 · ownership.xml · nonDerivative · entry 1 Patel Sandip I · CIK 0001843601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,334 F1 · shares: The Reporting Person purchased 501 units at a price of $10.335 per unit, for an aggregate purchase price of $5,177.84. Each unit consists of one share of common stock and one warrant to purchase one-half of one share of common stock. The warrants included in the units will become exercisable, if at all, on the later of one year after the closing of the Issuer's initial public offering or the consummation of the Issuer's initial business combination. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.